Julie Delyon

2.1k total citations
59 papers, 985 citations indexed

About

Julie Delyon is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Julie Delyon has authored 59 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 21 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Julie Delyon's work include Melanoma and MAPK Pathways (18 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cutaneous Melanoma Detection and Management (12 papers). Julie Delyon is often cited by papers focused on Melanoma and MAPK Pathways (18 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cutaneous Melanoma Detection and Management (12 papers). Julie Delyon collaborates with scholars based in France, United States and Switzerland. Julie Delyon's co-authors include Célèste Lebbé, Nicolas Dumaz, Émilie Lanoy, Caroline Robert, D. Lefeuvre, Céu Mateus, Émilie Routier, Laurence Zitvogel, Barouyr Baroudjian and Alexander M.M. Eggermont and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Oncogene.

In The Last Decade

Julie Delyon

56 papers receiving 972 citations

Peers

Julie Delyon
Cécile Pagès France
Suthee Rapisuwon United States
Sandra J. Meech United States
Adam Mor United States
Siddhartha Ganguly United States
Ayse U. Akarca United Kingdom
Van Anh Trinh United States
Alejandra Flores-Chávez Spain
Zeba N. Singh United States
Troy Z. Horvat United States
Cécile Pagès France
Julie Delyon
Citations per year, relative to Julie Delyon Julie Delyon (= 1×) peers Cécile Pagès

Countries citing papers authored by Julie Delyon

Since Specialization
Citations

This map shows the geographic impact of Julie Delyon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Delyon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Delyon more than expected).

Fields of papers citing papers by Julie Delyon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Delyon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Delyon. The network helps show where Julie Delyon may publish in the future.

Co-authorship network of co-authors of Julie Delyon

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Delyon. A scholar is included among the top collaborators of Julie Delyon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Delyon. Julie Delyon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Delyon, Julie, et al.. (2024). PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors. Cell Communication and Signaling. 22(1). 559–559.
2.
Delyon, Julie, Baptiste Louveau, Fanélie Jouenne, et al.. (2023). TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro. Cancers. 15(11). 2888–2888. 7 indexed citations
3.
Lebbé, Célèste, et al.. (2023). Endemic Kaposi’s Sarcoma. Cancers. 15(3). 872–872. 9 indexed citations
4.
Delyon, Julie & Olivier Michielin. (2023). Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk–benefit ratio. The Lancet Oncology. 25(1). 3–5. 1 indexed citations
5.
Herms, F., Barouyr Baroudjian, Julie Delyon, et al.. (2022). Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study. Acta Dermato Venereologica. 102. adv00740–adv00740. 12 indexed citations
6.
Goldwirt, Lauriane, Baptiste Louveau, Barouyr Baroudjian, et al.. (2021). Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study. Cancer Chemotherapy and Pharmacology. 88(3). 427–437. 6 indexed citations
7.
Oulès, Bénédicte, Samia Mourah, Barouyr Baroudjian, et al.. (2021). Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 480(2). 475–480. 6 indexed citations
8.
Gérard, Camille L., Julie Delyon, Alexandre Wicky, et al.. (2021). Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews. 101. 102227–102227. 72 indexed citations
9.
Battistella, Maxime, Julie Delyon, Jean‐Marc Gornet, et al.. (2020). Une complication digestive rare sous anti-PD-1 (pembrolizumab). Annales de Pathologie. 40(4). 320–323. 3 indexed citations
10.
Geoffroy, Pierre A., Julie Delyon, Marion Strullu, et al.. (2020). Standardized Patients or Conventional Lecture for Teaching Communication Skills to Undergraduate Medical Students: A Randomized Controlled Study. Psychiatry Investigation. 17(4). 299–305. 18 indexed citations
11.
Delyon, Julie, Matthieu Resche‐Rigon, M. Renaud, et al.. (2020). 1077MO PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: A multicenter phase II study. Annals of Oncology. 31. S732–S732. 7 indexed citations
12.
Delyon, Julie, Laurence Le Cleach, Sarah Guégan, et al.. (2020). Deep cutaneous fungal infections in solid-organ transplant recipients. Journal of the American Academy of Dermatology. 83(2). 455–462. 11 indexed citations
13.
Delyon, Julie, Célèste Lebbé, & Nicolas Dumaz. (2019). Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Current Opinion in Oncology. 32(2). 79–84. 26 indexed citations
14.
Baroudjian, Barouyr, et al.. (2018). Avancées thérapeutiques récentes dans la prise en charge du carcinome à cellules de Merkel. Bulletin du Cancer. 106(1). 64–72. 5 indexed citations
15.
Delyon, Julie, Josette André, Nicolás Ortonne, et al.. (2017). PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene. 36(23). 3252–3262. 27 indexed citations
16.
Delyon, Julie, et al.. (2016). Hypoxia and MITF regulate KIT oncogenic properties in melanocytes. Oncogene. 35(38). 5070–5077. 7 indexed citations
17.
Delyon, Julie, Michele Maio, & Célèste Lebbé. (2015). The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. Seminars in Oncology. 42(3). 387–401. 22 indexed citations
18.
Delyon, Julie, Nicolás Ortonne, Emmanuel Benayoun, et al.. (2015). Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker. Journal of the American Academy of Dermatology. 73(3). 484–490. 35 indexed citations
19.
Delyon, Julie, et al.. (2015). Gestion des effets secondaires cutanés des chimiothérapies et thérapies ciblées. Soins. 60(796). 17–24. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cécile Pagès Breakdown of academic impact, for papers by Suthee Rapisuwon Breakdown of academic impact, for papers by Sandra J. Meech Breakdown of academic impact, for papers by Adam Mor Breakdown of academic impact, for papers by Siddhartha Ganguly Breakdown of academic impact, for papers by Ayse U. Akarca Breakdown of academic impact, for papers by Van Anh Trinh Breakdown of academic impact, for papers by Alejandra Flores-Chávez Breakdown of academic impact, for papers by Zeba N. Singh Breakdown of academic impact, for papers by Troy Z. Horvat
Rankless by CCL
2026